Pembrolizumab blocks the action of the tumor - surface protein PD - 1, which many cancers use to hide themselves from immune system T cells.
Not exact matches
We are currently waiting for the results of several trials including EORTC 1325 which is investigating
pembrolizumab, a PD - 1 checkpoint
blocking antibody, compared to placebo in the adjuvant setting.»
Pembrolizumab works by binding to PD - 1 and
blocking the interaction between PD - 1 and its ligands, PD - L1 and PD - L2, thereby activating T lymphocyte cells which may affect both tumour cells and healthy cells.
Once they identified this pathway, Hanks and colleagues conducted laboratory tests of a molecule that
blocks melanoma cells from going stealth, enabling the immune system to mount a direct attack while also enhancing the function of current immunotherapies such as
pembrolizumab and nivolumab.
By binding to and
blocking certain molecules on T cells, in this case a molecule called PD - 1,
pembrolizumab «takes the brakes off» the immune response, allowing a more powerful response to cancer.
The phase II part of a phase Ib / II study (ClinicalTrials.gov identifier: NCT02263508; MASTERKEY - 265)[24] assessing the safety and efficacy of T - VEC in combination with the PD - 1 —
blocking antibody
pembrolizumab in previously untreated, unresected stage IIIB / IV melanoma is evaluating confirmed ORR by irRECIST at week 24.
Favorable responses with minimal toxicities in monotherapy trials have led to the first melanoma studies of T - VEC in combination with the cytotoxic T - lymphocyte — associated antigen 4 inhibitor ipilimumab and, separately, with the programmed death 1 —
blocking antibody
pembrolizumab.